Virtual Symposium - Bridging the Gap in the Diagnosis and Management of Postmenopausal Osteoporosis
Osteoporosis is a prevalent condition and a major health problem, but particularly more in postmenopausal women. Approximately 2 million osteoporosis-related fractures occur annually in the US, and more than 70% of these occur in women. Furthermore, osteoporosis carries a significant burden, estimated to be at $57 billion in 2018 and projected to reach more than $95 billion by year 2040.
Despite these impacts, postmenopausal osteoporosis remains underdiagnosed and undertreated. New guidelines that incorporate all the available treatment options have been recently published, however, diagnosis and treatment gaps may persist, as questions remain about the risk assessment, diagnostic interpretation, as well as therapy selection, monitoring, and appropriate switching or tapering off. During this symposium, multi-disciplinary experts will overview the updates in postmenopausal osteoporosis screening, diagnosis and management, as well as the individualization of treatment in this setting.
This activity is designed for endocrinologists, obstetricians, gynecologists, midwives, diabetologists, primary care physicians, cardiologists, lipidologists, and as well as nurses, nurse practitioners, and pharmacists.
After completing this activity, the participant should be better able to:
- Summarize recent advances in the screening and diagnostic approaches for postmenopausal osteoporosis.
- Review recent guideline updates for the management of postmenopausal osteoporosis.
- Develop individualized treatment regimens to reduce the risk of fracture and minimize bone density decline in postmenopausal women with osteoporosis based on updated guidelines, available treatment options, and patient-specific risk factors.
Pam Taub, MD, FACC (Chair)
Associate Professor of Medicine
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
UC San Diego Health System
Division of Cardiovascular Medicine
La Jolla, CA
Dr. Taub discloses the following:
Salary: UC San Diego
Consulting Fees: Amgen, Sanofi/Regeneron, Novo-nordisk, Esperion Therapeutics, Boehringer-Ingelheim
Contracted Research: Grant: Federal Emergency Management Agency, National Institutes of Health, American Heart Association; Research Support: Applied Therapeutics
Ownership Interest less than 5%: Epirium Bio: Stock/Shareholder
Kathryn Macaulay, MD
Director, UCSD Menopause Health Program
Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences
UC San Diego Health
San Diego, CA
Dr. Macauley has nothing to disclose.
Rachel Pessah-Pollack, MD, FACE
Clinical Associate Professor of Medicine
Department of Endocrinology, Diabetes & Metabolism
NYU Langone Health
New York, NY
Dr. Pessah-Pollack discloses the following:
Consulting Fees: Boehringer Ingelheim/Eli-Lilly
Other: CME: Medscape, Health Monitor
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by educational funding provided by Amgen.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-21-2854-H01-P.
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
CONTINUING DIETICIAN EDUCATION
This program offers 1.0 CPEUs for dieticians.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period June 23, 2021 through June 23, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.